PRRT2 and familial Mediterranean fever: While our previous work demonstrated a shift in a dose–response experiment between monocytes of FMF patients and of healthy donors, here we identified an “all or nothing” response that discriminates FMF patients’ monocytes from healthy donors’ monocytes across a large concentration of PKC superfamily inhibitors.